Use of a matrix for orally administering sustained release magnesium, and composition containing said matrix
First Claim
Patent Images
1. A composition for oral administration, in tablet form, of magnesium with progressive release, comprising:
- a matrix constituting a core comprising(A) 90 to 110 parts by weight of magnesium, the source of magnesium being MgCl2.9/2H2O,(B1) 180 to 190 parts by weight of hydroxypropylmethylcellulose,(B2) 19.8 to 22.2 parts by weight of glyceryl behenate,(C1) 10 to 12 parts by weight of lactose, and(C2) 10 to 12 parts by weight of colloidal silica; and
a film coating of(D) 15 to 75 parts by weight of a substance selected from shellac, cellulose ethers and mixtures thereof,wherein the composition exhibits, in vitro after 2 h in a 0.1N HCl medium, a rate of dissolution (δ
) of the magnesium comprised therein of greater than or equal to 20% and less than or equal to 60%.
0 Assignments
0 Petitions
Accused Products
Abstract
A tablet for oral administration comprises a matrix of progressive and continuous released magnesium. For the administration of 90 to 110 parts by weight of magnesium, the matrix comprises 180 to 190 parts by weight of hydroxypropylmethylcellulose, 19.8 to 22.2 parts by weight of glyceryl behenate, 10 to 12 parts by weight of lactose and 10 to 12 parts by weight of colloidal silica. A non-enteric protective coating that slows down the gastric dissolution of the magnesium may comprise 15 to 75 parts by weight of shellac, cellulose ether or a mixture thereof. The tablet may be administered to patients in need thereof.
-
Citations
19 Claims
-
1. A composition for oral administration, in tablet form, of magnesium with progressive release, comprising:
-
a matrix constituting a core comprising (A) 90 to 110 parts by weight of magnesium, the source of magnesium being MgCl2.9/2H2O, (B1) 180 to 190 parts by weight of hydroxypropylmethylcellulose, (B2) 19.8 to 22.2 parts by weight of glyceryl behenate, (C1) 10 to 12 parts by weight of lactose, and (C2) 10 to 12 parts by weight of colloidal silica; and a film coating of (D) 15 to 75 parts by weight of a substance selected from shellac, cellulose ethers and mixtures thereof, wherein the composition exhibits, in vitro after 2 h in a 0.1N HCl medium, a rate of dissolution (δ
) of the magnesium comprised therein of greater than or equal to 20% and less than or equal to 60%. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
-
9. A method comprising:
-
orally administering, in tablet form, a therapeutically or cosmetically effective amount of a progressive release magnesium composition to a patient in need thereof, wherein the composition comprises; a matrix constituting a core containing, for administration of 90 to 110 parts by weight of magnesium, the source of magnesium being MgCl2.9/2H2O, the following additional ingredients;
180 to 190 parts by weight of hydroxypropylmethylcellulose, 19.8 to 22.2 parts by weight of glyceryl behenate, 10 to 12 parts by weight of lactose and 10 to 12 parts by weight of colloidal silica, anda protective coating that slows down gastric dissolution of the magnesium, wherein the composition exhibits, in vitro after 2 h in a 0.1N HCl medium, a rate of dissolution (δ
) of the magnesium comprised therein of greater than or equal to 20% and less than or equal to 60%. - View Dependent Claims (10, 11, 12, 13)
-
-
14. A progressive release magnesium tablet for oral administration, comprising:
-
a matrix constituting a core containing a mixture of 90 to 110 parts by weight of magnesium, the source of magnesium being MgCl2.9/2H2O, 180 to 190 parts by weight of hydroxypropylmethylcellulose, 19.8 to 22.2 parts by weight of glyceryl behenate, 10 to 12 parts by weight of lactose, and 10 to 12 parts by weight of colloidal silica; and a film coating containing 15 to 75 parts by weight of a substance selected from shellac, cellulose ethers and a mixture thereof, wherein the tablet exhibits, in vitro after 2 h in a 0.1N HCl medium, a rate of dissolution (δ
) of the magnesium comprised therein of greater than or equal to 20% and less than or equal to 60%. - View Dependent Claims (15, 16, 17, 18, 19)
-
Specification